After page 21, insert the following Abstract as new page 22:

Abstract of the Invention

The invention concerns a topical composition comprising an emulsion of at least one discontinuous phase in a continuous phase, the or each discontinuous phase including a eutectic mixture of first and second pharmaceutically acceptable components which are both pharmacologically active agents and the continuous phase being provided by a pharmaceutically acceptable carrier, the eutectic mixture having a melting point below 40 °C. The topical composition may additionally comprise, in the eutectic mixture, a third or fourth pharmaceutically acceptable component.

On page 5, lines 4-11, replace the paragraph with the following new paragraph:

The present invention surprisingly overcomes the problems referred to hereinbefore, which hinder topical drug absorption, by providing a topical composition comprising a eutectic mixture of at least two pharmaceutically acceptable components which are both pharmacologically active agents in their lipophilic (substantially water-insoluble) form, the eutectic mixture being dispersed in, but not substantially dissolved in, a hydrophilic, pharmaceutically acceptable carrier.

On page 5, lines 13-23, replace the paragraph with the following new paragraph:

Accordingly, the invention provides a topical composition comprising an emulsion of at least one discontinuous phase in a continuous phase, the or each discontinuous phase including a eutectic mixture of first and second pharmaceutically acceptable components which are both pharmacologically active agents and the continuous phase being provided by a pharmaceutically acceptable carrier, the eutectic mixture having a melting point below 40°C. Preferably, the first pharmacologically active agent has a melting point between 35 and 75°C, preferably 40-50°C, and the second pharmacologically active agent has a melting point between -40 and 150°C, preferably between -5 and 90°C.

On page 8, lines 4-9, replace the paragraph with the following new paragraph:

The pharmaceutically acceptable component may also be an agent not intended for use in the prophylaxis or therapy of any condition affecting the health of the human or animal species and includes, but is not limited to, lauric acid, stearyl alcohol, menthol, thymol, cinnamic acid or an ester thereof.

On page 8, lines 11-24, replace the paragraph with the following new paragraph:

The pharmaceutically acceptable carrier according to this invention should be suitable for administration of the eutectic mixture; should not adversely interfere with the formation and stability of said mixture; and should be suitable for topical